Investigational drug · Phase 3
AGN-151586
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Forehead Lines, Glabellar Lines.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
10
Any phase or sponsor naming "AGN-151586"
First trial start
2024
Mar 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AGN-151586", any sponsor or status.
Conditions studied
As listed on its trial records.
- Forehead Lines
- Glabellar Lines
Largest trials
Live from ClinicalTrials.gov: studies naming "AGN-151586" as an intervention, largest first.
- A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05248893 · 992 participants · Start Feb 25, 2022 · Primary completion Jun 26, 2023
Drug: AGN-151586 · For: Glabellar Lines
Sites: Birmingham, Alabama; Glendale, Arizona; Los Angeles, California · 43 sites in all
- A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05248867 · 638 participants · Start Mar 16, 2022 · Primary completion Mar 17, 2023
Drug: Placebo; AGN-151586 · For: Glabellar Lines
Sites: Birmingham, Alabama; Encino, California; Los Angeles, California · 38 sites in all
- A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar LinesPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05248880 · 309 participants · Start Mar 8, 2022 · Primary completion Feb 1, 2023
Drug: AGN-151586; Placebo · For: Glabellar Lines
Sites: Scottsdale, Arizona; Newport Beach, California; Redondo Beach, California · 17 sites in all
- AGN-151586 Dose-Ranging Study for Treatment of Glabellar LinesPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT04096326 · 198 participants · Start Sep 26, 2019 · Primary completion Sep 9, 2020
Drug: AGN-151586; Placebo · For: Glabellar Lines
Sites: Fremont, California; Santa Monica, California; Miami, Florida · 9 sites in all
- A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar LinesPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT06308198 · 161 participants · Start Mar 29, 2024 · Primary completion Feb 26, 2025
Drug: AGN-151586; Placebo · For: Glabellar Lines
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 12 sites in all
- A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT07756580 · 143 participants · Start Aug 10, 2026 · Primary completion Feb 2027
Drug: AGN-151586; BOTOX · For: Glabellar Lines
Sites: Glendale, Arizona; Newport Beach, California; Vista, California · 8 sites in all
- A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT06834789 · 132 participants · Start Feb 18, 2025 · Primary completion Nov 3, 2025
Drug: AGN-151586; OnabotulinumtoxinA and 1 more · For: Glabellar Lines
Sites: Scottsdale, Arizona; Newport Beach, California; Redondo Beach, California · 8 sites in all
AbbVieAbbVie (ABBV)
NCT05496335 · 90 participants · Start Aug 30, 2022 · Primary completion May 30, 2023
Drug: AGN-151586; BOTOX and 1 more · For: Glabellar Lines
Sites: Newport Beach, California; San Diego, California; Greenwood Village, Colorado · 10 sites in all
- A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult ParticipantsActive, not recruiting
AbbVieAbbVie (ABBV)
NCT07730554 · 84 participants · Start Jul 22, 2026 · Primary completion Oct 2026
Drug: AGN-151586 · For: Forehead Lines
Sites: Newport Beach, California; New York, New York; Wilmington, North Carolina · 5 sites in all
AbbVieAbbVie (ABBV)
NCT06151561 · 24 participants · Start Jan 5, 2024 · Primary completion Apr 3, 2024
Drug: AGN-151586; Placebo · For: Moderate to Severe Glabellar Lines
Sites: Central District, Japan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.